Clinical trials: Advanced Intestinal Cancer
Rectal Cancer
Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer
The standard treatment for stage 2/3 rectal cancer is neoadjuvant 5-Fu based chemoradiation. However, preoperative radiation cause kinds of adverse events, some were irreversible. And the survival benefit was not obvious.
- Trial name
- FORTUNE (NCT02217020)
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Neoadjuvant Treatment, Rectal Cancer
Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Prospectively Investigate the effectiveness and safety of anlotinib hydrochloride combined with Capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.
- Conditions
- Neoadjuvant Treatment, Rectal Cancer, Anlotinib
- Trial name
- NCT04620473
- Testing
- Anlotinib+Capeox, Capeox
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Rectal Cancer, Radiotherapy
IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.
The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small…
- Conditions
- Rectal Cancer, Radiotherapy, Toxicity Due to Radiotherapy
- Trial name
- NCT06160570
- Testing
- Intensive Modulated Radiation Therapy, 3-Dimension Conformal Radiation Therapy
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Rabin Medical Center
Colorectal Cancer
Polyprev: Study to Compare Fecal Immunochemical Test With Endoscopic Surveillance After Advanced Adenoma Resection in Fecal Immunochemical Test Colorectal Cancer Screening Programs.
Colorectal cancer (CRC) screening programs have been implemented to reduce the burden of the disease. When an advanced colonic lesions is detected, it is recommended to perform endoscopic surveillance with different intervals…
- Trial name
- NCT04967183
- Testing
- Annual FIT, Endoscopic surveillance.
- Where
- Spain
- Volunteers
- 3,788 people, healthy volunteers welcome
- Sponsor
- Fundacin Biomedica Galicia Sur
Rectal Cancer
Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer
This research investigates the role of the gut microbe in patients receiving radioimmunotherapy with locally advanced microsatellite-stable (MSS) rectal cancer.
- Trial name
- NCT06898359
- Testing
- Radioimmunotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Yanhong Deng
Colorectal Cancer
FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer
the aim of this study is to observe the effect of irinotecan-based regimen in patients with advanced colorectal cancer.
- Trial name
- NCT01566942
- Testing
- Oxaliplatin, Irinotecan
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Colonic Neoplasms, Chemotherapy Effect
The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Colon cancer is one of the most lethal malignancies, and colorectal cancer ranks the fifth leading cause of tumor-related mortality in China. FOLFOX is the recommended adjuvant/ neoadjuvant treatment for advanced colon cancer.
- Trial name
- JSFOL (NCT03985891)
- Testing
- Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Metastatic Colorectal Cancer (CRC)
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06825624
- Testing
- HS-20093, Bevacizumab, 5-FU
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Hansoh BioMedical R&D Company
Adenocarcinoma
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with advanced or metastatic adenocarcinoma of the small intestine.
- Trial name
- NCT03000179
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colorectal Neoplasms
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan.
- Trial name
- NCT00361842
- Testing
- CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
- Where
- 13 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Cancer
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
In this single-center,open-label, randomized, phase II study, the efficacy and feasibility of GSL synthetase inhibitor in combination with immune checkpoint inhibitor and/or regorafenib therapeutic regimen will be evaluated in…
- Trial name
- NCT06558773
- Testing
- Regorafenib+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor +Regorafenib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Colorectal Cancer
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with…
- Trial name
- NCT00003225
- Testing
- amifostine trihydrate, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer, Neuroendocrine
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
The study consists of two parts: Drug Interaction (Pharmacokinetic) Phase and Pharmacodynamic Phase The primary study objective for the Drug Interaction Study is to determine the pharmacokinetic interactions between RAD001 and…
- Conditions
- Cancer, Neuroendocrine, Ovarian Cancer, Colon Cancer
- Trial name
- NCT01149434
- Testing
- JI-101, Everolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Utah
Colorectal Cancer
Virtual Reality for Improving Pain and Distress in Patients With Advanced Stage Colorectal Cancer
Patients with advanced colorectal cancer often experience high levels of debilitating pain and pain-related psychological distress. Pain in cancer patients is typically treated with analgesics.
- Trial name
- VR Blue (NCT04069702)
- Testing
- VR Blue
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase)…
- Conditions
- Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
- Trial name
- SPICE (NCT02636036)
- Testing
- enadenotucirev, nivolumab
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Akamis Bio
Colorectal Cancer
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the Therapy of Advanced Colorectal Cancer.
- Trial name
- NCT03397199
- Testing
- Apatinib + S-1
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Henan Cancer Hospital
Colorectal Cancer
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type…
- Trial name
- PARADIGM (NCT02394795)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Where
- 155 sites in Japan
- Volunteers
- 823 people
- Sponsor
- Takeda
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2).
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
- Trial name
- NCT05091528
- Testing
- SBT6050, trastuzumab deruxtecan, tucatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Silverback Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.